These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 35475910)

  • 1. The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity.
    Tumino N; Nava Lauson CB; Tiberti S; Besi F; Martini S; Fiore PF; Scodamaglia F; Mingari MC; Moretta L; Manzo T; Vacca P
    Int J Cancer; 2023 Apr; 152(8):1698-1706. PubMed ID: 36468179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
    Liu M; Jin Q; Wang H; Li Y
    Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic approaches to enhance natural killer cell cytotoxicity.
    Stenger TD; Miller JS
    Front Immunol; 2024; 15():1356666. PubMed ID: 38545115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Immune Checkpoint Inhibitor Treatment Outcomes and Body Composition Factors in Metastatic Renal Cell Carcinoma Patients.
    Takei K; Kijima T; Okubo N; Kurashina R; Kokubun H; Uematsu T; Betsunoh H; Yashi M; Kamai T
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of myokines in cancer: crosstalk between skeletal muscle and tumor.
    Park SY; Hwang BO; Song NY
    BMB Rep; 2023 Jul; 56(7):365-373. PubMed ID: 37291054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of interleukin-15 in the development and treatment of hematological malignancies.
    Sindaco P; Pandey H; Isabelle C; Chakravarti N; Brammer JE; Porcu P; Mishra A
    Front Immunol; 2023; 14():1141208. PubMed ID: 37153603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
    Li F; Liu S
    Front Immunol; 2022; 13():1083462. PubMed ID: 36601109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
    Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
    Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab in T-cell malignancies.
    Dearden CE; Matutes E; Catovsky D
    Med Oncol; 2002; 19 Suppl():S27-32. PubMed ID: 12180489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-15 augments NK cell-mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies.
    Miljkovic MD; Dubois SP; Müller JR; Bryant B; Ma E; Conlon KC; Waldmann TA
    Blood Adv; 2023 Feb; 7(3):384-394. PubMed ID: 35475910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-15 in the Combination Immunotherapy of Cancer.
    Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
    Front Immunol; 2020; 11():868. PubMed ID: 32508818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
    Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.
    Zhang M; Wen B; Anton OM; Yao Z; Dubois S; Ju W; Sato N; DiLillo DJ; Bamford RN; Ravetch JV; Waldmann TA
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10915-E10924. PubMed ID: 30373815
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.